Apnimed, Inc. Common Stock (APMD) - Total Assets
Based on the latest financial reports, Apnimed, Inc. Common Stock (APMD) holds total assets worth $342.63 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See APMD share price today for real-time trading data and today's change.
Apnimed, Inc. Common Stock - Total Assets Trend (2024–2025)
This chart illustrates how Apnimed, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see cash efficiency ratio of Apnimed, Inc. Common Stock for how efficiently the company converts equity into cash flow.
Apnimed, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Apnimed, Inc. Common Stock's total assets of $342.63 Million consist of 61.8% current assets and 38.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.5% |
| Accounts Receivable | $959.00K | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2024–2025)
This chart illustrates how Apnimed, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Apnimed, Inc. Common Stock short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apnimed, Inc. Common Stock's current assets represent 61.8% of total assets in 2025, a decrease from 67.1% in 2024.
- Cash Position: Cash and equivalents constituted 57.5% of total assets in 2025, down from 62.6% in 2024.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2024.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Apnimed, Inc. Common Stock Competitors by Total Assets
Key competitors of Apnimed, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
Apnimed, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.65 | - | - |
| Quick Ratio | 8.65 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $293.61 Million | - | - |
Apnimed, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Apnimed, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.32 |
| Latest Market Cap to Assets Ratio | 13.59 |
| Asset Growth Rate (YoY) | -33.3% |
| Total Assets | $72.87 Million |
| Market Capitalization | $990.40 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Apnimed, Inc. Common Stock's assets at a significant premium (13.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Apnimed, Inc. Common Stock's assets decreased by 33.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Apnimed, Inc. Common Stock (2024–2025)
The table below shows the annual total assets of Apnimed, Inc. Common Stock from 2024 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $72.87 Million | -33.28% |
| 2024-12-31 | $109.22 Million | -- |
About Apnimed, Inc. Common Stock
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Ca… Read more